China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome
August 13, 2024Clinical Research, Research and Development Ascentage Pharma, Oncology
The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
First Nasal Spray for Treatment of Anaphylaxis approved by FDA
August 12, 2024Research and Development Emergency Medicine, FDA, anaphylaxis, epinephrine, nasal
ARS Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their epinephrine nasal spray, neffy, …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
August 12, 2024Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells
Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …
Richmond promotes new Director of Communications and Participant Engagement
August 9, 2024Research and Development Corporate, Richmond Pharmacology, appointment, pharmaceutical
Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
August 9, 2024Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
Cresset collaborates with global leaders Enamine to enable the design of new Targeted Protein Degraders
August 9, 2024Research and Development Corporate, Cresset, Cressete, Enamine, Microbiology, Targeted Protein Degraders
This week, drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research …
Pharma services boom in China as CPHI & PMEC China posts record attendance
August 8, 2024Conferencing, Events & Incentives, Public Relations, Sales and Marketing CPHI China, PMEC China, pharma
Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment
August 6, 2024Research and Development Levicept, Rheumatology, osteoarthritis, trial
Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.
Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health
August 6, 2024Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial
Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
August 6, 2024Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …
Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception
August 5, 2024Research and Development Contraception, UK, contraception, license extension
Gedeon Richter UK Ltd. (“Richter”) today announced that the Medicines Health Regulatory Authority (MHRA) has authorised an extension to the …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 5, 2024Research and Development GSK, Oncology, Reproductive health, endometrial cancer
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA for spinal robotics and navigation platform
August 5, 2024Research and Development 501k clearance, Johnson & Johnson MedTech, Orthopaedics, orthopaedics, robotics, spinal, surgery
Today, the Orthopaedics branch of Johnson & Johnson MedTech, DePuy Synthes, has announced that their surgical robotics system VELYS active …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
August 2, 2024Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
Novo Holdings Invests in Oxford Nanopore Technologies
August 1, 2024Research and Development Microbiology, Novo Holdings, Oxford Nanopore Technologies, biopharmacuticals, biotech, data, drug therapies, investment
leading life science investor Novo Holdings, announced a £50m investment in Oxford Nanopore Technologies. Oxford Nanopore Technologies is a leading …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
